Latest Soligenix News & Updates

See the latest news and media coverage for Soligenix. We track all announcements, press releases, and industry mentions in real time, all in one place.

Soligenix

Biopharmaceutical company developing rare disease treatments and biodefense vaccines

soligenix.com

Headquarters: Princeton, United States
Founded year: 1987
Company type: Public company
Number of employees: 25–50
Industry: Pharmaceuticals

Last updated September 21

Latest news about Soligenix

In short: Soligenix discontinued its HyBryte CTCL program after a Phase 3 futility halt and narrowed its net loss to $2.0 million in Q2 2026.

Company announcements

August 7 Soligenix

Soligenix announces second quarter 2026 financial results and pipeline updates

Net loss narrowed to $2.0 million, with $9.8 million cash. The company discontinued its HyBryte program and continues advancing SGX945 and ThermoVax.

June 8 Soligenix

Soligenix applies for Bundibugyo Ebola vaccine funding

The company plans to submit an application to CEPI by June 12, 2026, leveraging its ThermoVax platform and prior filovirus vaccine data.

May 26 Soligenix

Soligenix notes suitability of its vaccine platform for Bundibugyo virus

The platform could enable rapid development of a thermostable subunit vaccine for the ongoing Ebola outbreak in Congo.

May 8 Soligenix

Soligenix announces Q1 2026 financial results and FLASH2 study halt

Net loss was $2.8 million; cash $6.0 million; FLASH2 trial halted for futility; strategic options including M&A to be evaluated.

Media coverage

September 21 MarketScreener

Soligenix Approves Amendment to the Company?S Second Amended and Restated Certificate of Incorporation

Second Amended and Restated Certificate of Incorporation, which increased the number of authorized shares of Common Stock from 75,000,000 to 125,000,000. The Charter Amendment became...

August 10 Yahoo Finance

Soligenix culls topical lymphoma asset after Phase III miss

Soligenix has terminated the late-stage development programme for its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte, after the drug failed to show early signs of...

August 7 Yahoo Finance

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an...

June 28 The Globe and Mail

Soligenix Expands At-the-Market Equity Offering Capacity

Soligenix ( (SNGX)) has shared an announcement. On June 26, 2026, Soligenix, Inc. increased the maximum aggregate amount of common stock it may issue under...

Never miss news about Soligenix

Track Soligenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Soligenix competitors & trending companies

Browse news for competitors to Soligenix and other trending companies.